Author

Brandon Murphy

University of UtahORCID 0000-0002-5692-3643Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Martin McMahoniD· 3 shared Conan Grant KinseyiD· 2 shared Kayla T. O’TooleiD· 2 shared Sanjana Srinivas BoggaramiD· 2 shared Adamaris Martinez· 1 shared Amanda JiangiD· 1 shared Anastasia Proveyeka· 1 shared Aparna HegdeiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Martin McMahonORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma

Mona Foth, Wontak Kim, Kayla T. O’Toole, Brandon Murphy, Montserrat Justo-Garrido, Sanjana Srinivas Boggaram, Phaedra C. Ghazi, Euan Brennan, M. Isaac Wright, Tate Shepherd, Emilio Cortes-Sanchez, Yingyun Wang, Jennifer A. Roth, Matthew G. Rees, Melissa M. Ronan, , Martin McMahon

This study identifies RAS(ON) inhibitors effective against NRAS-mutated melanoma and reveals resistance mechanisms through Ppia and Map2k1 mutations.

Cancer Research · May 22, 2026Peer-reviewedCancer Biology

Characterization of the BRAF interactome identifies BRAFV600ETP53 interaction in melanoma

Kayla T. O’Toole, Adamaris Martinez, Brandon Murphy, Anastasia Proveyeka, Gabriela Fort, Fatima Al-Sudani, Sanjana Srinivas Boggaram, Elliott L. Paine, Deevya Baral, Joshua Lyon Andersen, Gennie Lynne Parkman, Eric L. Snyder, Robert L. Judson‐Torres, Martin McMahon

The paper identifies a novel interaction between BRAFV600E and TP53 in melanoma, suggesting that BRAFV600E inactivates TP53, explaining the rarity of TP53 alterations in this cancer type.

bioRxiv · Jun 20, 2025 · PreprintCancer Biology

BRAFV600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling

Mélanie A. Dacheux, Mengting Wu, Michael T. Scherzer, Monique Nillson, Brandon Murphy, Sophia S. Schuman, Zhenlin Ju, Trever Grant Bivona, Piro Lito, Matthew Gumbleton, Sonam Puri, Wallace Akerley, Jing Wang, Kaiwen Wang, John Victor Heymach, , Aria Vaishnavi

This study shows that BRAFV600E-driven lung cancer requires ERBB receptor signaling via ligand-mediated activation, and combined inhibition of BRAFV600E and ERBB improves therapeutic outcomes.

bioRxiv · May 4, 2025 · PreprintCancer Biology